Dupilumab in atopic dermatitis patients with chronic hepatitis B

Matsutani, Masako; Imai, Yasutomo; Nakatani‐Kusakabe, Minori; Natsuaki, Masaru; Yamanishi, Kiyofumi; Kanazawa, Nobuo

doi:10.1002/cia2.12209

Cited by 3 publications

(4 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Only one case report on two patients with chronic HBV infection in treatment with entecavir and DUP shows no viral reactivation (38) . Furthermore, in a prospective report of five patients treated with DUP who were HBV surface antigen positive and did not receive HBV medication no viral reactivation was detected (39) . TRA phase 3 clinical studies have not reported any cases of HBV reactivation, potentially reflecting trial exclusion criteria for patients with a history of HBV (11) DUP and TRA specifically inhibits Th2 immune responses while having limited effect on Th1 immune responses (40).…”

Section: Hepatitis B Virusmentioning

confidence: 98%

See 1 more Smart Citation

Biologics and small molecules treatment for moderate-to-severe atopic dermatitis patients with comorbid conditions and special populations: an Italian perspective

Guglielmo,

Deotto,

Naldi

et al. 2023

Dermatol Reports

View full text Add to dashboard Cite

This comprehensive review offers a detailed look at atopic dermatitis (AD) treatment in Italy, focusing primarily on the use of biologics and small molecules. In response to advancing knowledge of AD's causes and treatments, there's a global need for updated guidelines to provide physicians with a more comprehensive clinical perspective, facilitating personalized treatment strategies. Dupilumab, a groundbreaking biologic, gained approval as a significant milestone. Clinical trials demonstrated its ability to significantly reduce AD severity scores, with an impressive 37% of patients achieving clear or nearly clear skin within just 16 weeks of treatment. Real-world studies further support its efficacy across various age groups, including the elderly, with a safety profile akin to that of younger adults. Tralokinumab, a more recent approval, shows promise in clinical trials, particularly among younger populations. However, its real-world application, especially in older individuals, lacks comprehensive data. JAK inhibitors like Upadacitinib, baricitinib, and abrocitinib hold substantial potential for AD treatment. Nevertheless, data remains limited for patients over 75, with older adults perceived to carry a higher risk profile. Integrated safety analyses revealed individuals aged 60 and above experiencing major adverse cardiovascular events and malignancies, underscoring the need for cautious consideration. While these therapies offer promise, especially among younger patients, further research is essential to determine their safety and efficacy in various populations, including pediatric, geriatric, and those with comorbidities. This review highlights the evolving landscape of AD treatment, with biologics and small molecules emerging as potent tools to enhance the quality of life for AD-affected individuals.

show abstract

Section: Hepatitis B Virusmentioning

confidence: 98%

“… 38 Furthermore, in a prospective report of five patients treated with DUP who were HBV surface antigen positive and did not receive HBV medication no viral reactivation was detected. 39 …”

Section: Patients With Past and Current Infectionsmentioning

confidence: 99%

Biologics and small molecules treatment for moderate-to-severe atopic dermatitis patients with comorbid conditions and special populations: an Italian perspective

Guglielmo,

Deotto,

Naldi

et al. 2023

Dermatol Reports

View full text Add to dashboard Cite

show abstract

“…Case reports suggest there is no increased risk of hepatitis B reactivation with the use of dupilumab. 81 …”

Section: Hepatitis B and The Use Of Ibsmentioning

confidence: 99%

Infections in the era of immunobiologicals

Romiti,

Hirayama,

Porro

et al. 2024

Anais Brasileiros de Dermatologia

View full text Add to dashboard Cite

“…98 Additionally, in a prospective report of five DUP-treated adult patients with AD who were HBV surface antigen positive and did not receive HBV therapy, close monitoring showed no clinically significant elevations in HBV DNA. 99 Since DUP, LEB, and TRA selectively suppress Th2 immune responses 100,101 and HBV suppression occurs through a Th1 response, these biologics are unlikely to cause HBV reactivation. There are no published data for patients with HBV treated with JAKis for AD.…”

Section: Past and Current Infections Of Interestmentioning

confidence: 99%

Expert consensus on the systemic treatment of atopic dermatitis in special populations

Adam

Gooderham

Beecker

et al. 2023

Acad Dermatol Venereol

View full text Add to dashboard Cite

With the increasing number of options for the treatment of moderate-to-severe atopic dermatitis, clinicians need guidance on a practical approach to selecting a systemic agent for specific patient populations. We convened an expert panel consisting of 12 members to conduct a literature review and summarize relevant data related to six scenarios of clinical interest: comorbid asthma, ocular surface disease, history of cancer, past and ongoing infections of interest (including herpes simplex virus, herpes zoster, hepatitis B, and tuberculosis), pregnancy and lactation, and the elderly. We performed a literature search and examined each clinical scenario with | 1143 ADAM et al.

show abstract

Dupilumab in atopic dermatitis patients with chronic hepatitis B

Abstract: The study protocol was approved by the Ethics Review Board of Hyogo College of Medicine and conformed to the ethical guidelines of the Declaration of Helsinki.

Cited by 3 publications

References 5 publications

Biologics and small molecules treatment for moderate-to-severe atopic dermatitis patients with comorbid conditions and special populations: an Italian perspective

Biologics and small molecules treatment for moderate-to-severe atopic dermatitis patients with comorbid conditions and special populations: an Italian perspective

Infections in the era of immunobiologicals

Expert consensus on the systemic treatment of atopic dermatitis in special populations

Contact Info

Product

Resources

About